Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 8/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18230612 | 0.79 | CHRNB2 (0.33) | — | |
| SCHEMBL8746923 | 0.77 | TLR4 (0.47) | TLR4RAB9ATSHRNPC1HPGD | |
| SCHEMBL16489094 | 0.77 | TLR4 (0.45) | TLR4RAB9ATSHRNPC1 | |
| SCHEMBL872474 | 0.77 | ALDH1A1 (0.40) | TLR4RAB9ATSHRNPC1 | |
| SCHEMBL18204555 | 0.76 | GSK3B (0.33) | RAB9ATSHRGSK3BGAAHPGD | |
| SCHEMBL18204504 | 0.76 | GRM1 (0.34) | TLR4RAB9ATSHRGSK3BGAA | |
| SCHEMBL18059820 | 0.76 | TLR4 (0.46) | TLR4RAB9ATSHRNPC1 | |
| SCHEMBL10229490 | 0.76 | TLR4 (0.44) | TLR4RAB9ATSHRNPC1HPGD | |
| SCHEMBL8746914 | 0.75 | TLR4 (0.42) | TLR4RAB9ATSHRNPC1GAA | |
| SCHEMBL19970479 | 0.75 | KDM4E (0.33) | RAB9ATSHRGSK3BGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3294706-A1 | CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-9828357-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-28 | — | — | US | disclosed |
| US-9611244-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-04 | — | — | US | disclosed |
| US-20170066737-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9533966-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-03 | — | — | US | disclosed |
| WO-2016182036-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-17 | — | — | WO | disclosed |
| US-20160326102-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-10 | — | — | US | disclosed |
| US-20160326133-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326102-A1 | CYCLIC COMPOUNDS | TLR4, TLR3, TLR1 | TLR4 1/4885RAB9A 3388/4885TSHR 3438/4885 |
| US-20160326133-A1 | CYCLIC COMPOUNDS | TLR4, TLR3, TLR1 | TLR4 1/4885RAB9A 3388/4885TSHR 3438/4885 |
| US-20170066737-A1 | CYCLIC COMPOUNDS | TLR4, TLR3, TLR1 | TLR4 1/4885RAB9A 3309/4885TSHR 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.